Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Profit After Tax (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Profit After Tax for 11 consecutive years, with -$1.7 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 55.62% to -$1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$12.2 million through Dec 2025, down 13.35% year-over-year, with the annual reading at -$12.2 million for FY2025, 13.35% down from the prior year.
  • Profit After Tax for Q4 2025 was -$1.7 million at Marker Therapeutics, up from -$2.0 million in the prior quarter.
  • The five-year high for Profit After Tax was $2.5 million in Q2 2023, with the low at -$12.4 million in Q3 2021.
  • Average Profit After Tax over 5 years is -$5.0 million, with a median of -$3.9 million recorded in 2024.
  • The sharpest move saw Profit After Tax skyrocketed 127.21% in 2023, then plummeted 187.16% in 2024.
  • Over 5 years, Profit After Tax stood at -$9.8 million in 2021, then surged by 68.83% to -$3.0 million in 2022, then increased by 9.96% to -$2.7 million in 2023, then crashed by 40.05% to -$3.8 million in 2024, then surged by 55.62% to -$1.7 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$1.7 million, -$2.0 million, and -$4.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.